Sandhill Capital Partners LLC Raises Stock Position in Johnson & Johnson $JNJ

Sandhill Capital Partners LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 27,686 shares of the company’s stock after purchasing an additional 1,035 shares during the quarter. Sandhill Capital Partners LLC’s holdings in Johnson & Johnson were worth $4,592,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. GM Advisory Group LLC boosted its stake in shares of Johnson & Johnson by 1.5% in the first quarter. GM Advisory Group LLC now owns 13,593 shares of the company’s stock valued at $2,254,000 after purchasing an additional 201 shares during the period. T. Rowe Price Investment Management Inc. acquired a new position in shares of Johnson & Johnson in the first quarter worth about $102,460,000. Asset Management Group Inc. boosted its holdings in Johnson & Johnson by 0.7% in the first quarter. Asset Management Group Inc. now owns 17,604 shares of the company’s stock valued at $2,920,000 after purchasing an additional 115 shares during the last quarter. Breed s Hill Capital LLC grew its stake in Johnson & Johnson by 4.4% during the 1st quarter. Breed s Hill Capital LLC now owns 3,530 shares of the company’s stock valued at $585,000 after purchasing an additional 150 shares in the last quarter. Finally, Capital Analysts LLC increased its holdings in Johnson & Johnson by 2.9% during the 1st quarter. Capital Analysts LLC now owns 44,284 shares of the company’s stock worth $7,344,000 after purchasing an additional 1,257 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $177.7060 on Wednesday. The stock has a market capitalization of $427.98 billion, a P/E ratio of 19.01, a P/E/G ratio of 2.24 and a beta of 0.41. The firm’s 50-day moving average price is $162.13 and its two-hundred day moving average price is $158.73. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $178.18. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. During the same period in the prior year, the firm earned $2.82 EPS. The business’s quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent analyst reports. Wall Street Zen cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday, July 18th. UBS Group boosted their target price on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, July 17th. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Benchmark raised Johnson & Johnson to a “strong-buy” rating in a report on Thursday, April 24th. Finally, Bank of America upped their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $174.50.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.